Mitja et al |
179 (85%) |
Necrotizing Skin Lesions, lung involvement,
CNS involvement, GI involvement, secondary infections, sepsis |
21
(25%) |
21 |
27 (15%) |
47 |
57% mortality rate of those with
suspected IRIS. |
Triana-Gonzalez et al |
10 (15.6) |
Intestinal obstruction/peritonitis,
lung involvement/ARDS, |
Not provided |
Not provided |
4 (40%) |
50 |
Risk factors for mortality: CD4 < 100, absence of ART,
>50 lesions at presentation. |
Miller et al |
40 (93%) |
Necrotizing Skin lesions, lung involvement,
CNS involvement, |
Not provided |
Not provided |
Not provided |
Not
provided |
Advocates combining anti-MPXV therapies with
progression. |
Riser et al
|
24 (89%)
|
Necrotizing skin lesions
|
24 (89%)
|
15
|
24 (100%)
*Only included deceased
|
68
|
23 of the 27 HIV+ patients had CD4 counts < 50
|
Hermanussen et al |
4 |
Necrotizing skin lesions, deep soft tissue
abscess/myositis, GI involvement, CNS involvement |
0 |
Not provided |
NA |
NA |
All patients treated with tecovirimat. Those with CD4
< 200 hospitalized > 2 weeks. |
Warner et al |
2 (100%) |
Necrotizing skin lesions, CNS involvement,
septic arthritis, secondary infections, sepsis |
2 (100%) |
33 |
1
(50%) |
68 |
Both patients with suspected IRIS. |
Pettit et al |
2 |
Necrotizing skin lesions, GI involvement, pulmonary
involvement, bacterial superinfection |
2 (100%) |
Not provided |
2
(100%) |
35 |
Both patients with suspected IRIS, treated with steroids
and pausing of ART. |
Filippov et al |
1 |
Necrotizing skin lesions, lung involvement, ocular
involvement |
Never on ART |
Never on ART |
1 |
74 |
Patient declined
ART, was treated with cidofovir, tecovirimat and VIGIV. |
Stafford et al |
1 |
Necrotizing skin and oral lesions |
0 |
immediate |
NA |
NA |
Patient treated with ART, tecovirimat and
cidofovir. |
Viguier et al |
1 |
Necrotizing skin lesions |
0 |
47 |
NA |
NA |
|
Thet et al |
1 |
Necrotizing skin lesions, GI involvement, bacterial
superinfection |
1 |
immediate |
NA |
NA |
Patient treated with ART,
tecovirimat, and VIGIV. Recovery did not begin until after VIGIV
administration. |
Caria et al |
1 |
Necrotizing skin lesions, GI involvement, lung
involvement, CNS involvement |
1 |
46 |
1 (100%) |
107 |
Patient
treated with ART, tecovirimat, and cidofovir. |
Martinez et al
|
0
*Case had CD4 count of 218 cells/mm3
|
Necrotizing skin lesions, GI involvement, rectal abscess, bacterial
superinfection
|
1
|
Not provided
|
NA
|
NA
|
Patient treated with ART, tecovirimat, cidofovir and VIGIV.
|